Malignant Pleural Mesothelioma Clinical Trial
Official title:
MesoTRAP: A Pilot Clinical Trial and Feasibility Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma Designed to Address Recruitment and Randomisation Uncertainties and Sample Size Requirements for a Phase III Trial.
Malignant pleural mesothelioma is a cancer, caused by asbestos, which currently affects 2500
people in the UK each year. The main symptom is breathlessness caused by fluid building up in
the space between the lung and the chest wall (pleural effusion). Treatment involves draining
the fluid to allow the lung to re-expand (pleurodesis). However, sometimes tumour growth over
the surface of the lung can prevent it from re-expanding. This 'trapped' lung results in
fluid re-accumulation and repeated drainage which can lead to discomfort and multiple
hospital visits.
One approach to dealing with 'trapped' lung in mesothelioma is to insert a thin tube
(Indwelling Pleural Catheter - IPC) into the space around the lung. The tube can stay in
place for a long time allowing patients to drain off fluid at home.
Another approach is a keyhole surgical operation (video-assisted thoracoscopic partial
pleurectomy/decortication - VAT-PD) to remove as much tumour as possible from the lining of
the lung to allow it to re-expand.
While both approaches are currently offered in clinical practice, it is not known which of
the two is most effective at relieving breathlessness. The only way to find out is to conduct
a research trial comparing the two. The Investigators plan to do this, but first of all need
to carry out a small pilot study to collect information necessary to help plan the full
study.
This is a multi-centre, open-label, randomised controlled pilot clinical trial and
feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication
(VAT-PD) with indwelling pleural catheter (IPC) in patients with trapped lung (TL) and
pleural effusion due to malignant pleural mesothelioma (MPM), aimed at addressing recruitment
and randomisation uncertainties as well as sample size requirements for a full phase III
study. 38 patients will be randomised and allocated in a 1:1 ratio to either VAT-PD or IPC.
The study will be undertaken at mesothelioma surgical centres with expertise in either IPC,
VAT-PD or both procedures, together with their linked non-surgical referral hospitals (hub
and spoke). Patients meeting all eligibility criteria will be informed about the study,
provided with a patient information sheet and given at least 24 hours to consider
participation.
Following consent, patients will be randomised, baseline measurements will be taken and a
procedure date will be arranged. Following the procedure follow-up visits at 6 weeks, 3, 6
and 12 months post-randomisation are planned to coincide with clinical care visits.
In parallel with the main study an observational sub-study will collect observational data on
a cohort of patients who have Malignant Pleural Mesothelioma and trapped lung, but who are
either not eligible to participate, or who decline to participate in the main study. Patients
in the Observational Sub-study will receive the same baseline and follow-up visits as those
in the main study, but will receive standard clinical care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037941 -
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
|
N/A | |
Completed |
NCT01675765 -
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
|
Phase 1 | |
Withdrawn |
NCT04201145 -
Pembrolizumab + Defactinib In Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT03048474 -
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT02369198 -
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
|
Phase 1 | |
Terminated |
NCT01870609 -
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT00886028 -
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00272558 -
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT02436733 -
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
|
Phase 2 | |
Completed |
NCT04843007 -
Alvopem® (Pemetrexed) Safety Assessment
|
||
Completed |
NCT01721018 -
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00797719 -
Short Neoadjuvant Hemithoracic IMRT for MPM
|
Phase 1/Phase 2 | |
Completed |
NCT00386815 -
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
Completed |
NCT04775446 -
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
|
||
Completed |
NCT01865045 -
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
|
||
Completed |
NCT01644994 -
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT00571298 -
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
|
Phase 1 | |
Recruiting |
NCT01343264 -
Trimodality Therapy for Malignant Pleural Mesothelioma
|
N/A | |
Active, not recruiting |
NCT04162015 -
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
|
Phase 1 |